Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan;5(1):41-50.
doi: 10.1177/1758834012458480.

New agents on the horizon in hepatocellular carcinoma

Andrew X Zhu  1
Affiliations

New agents on the horizon in hepatocellular carcinoma

Andrew X Zhu. Ther Adv Med Oncol. 2013 Jan.

Abstract

Despite the successful approval and extensive application of sorafenib, the prognosis for patients with advanced hepatocellular carcinoma (HCC) remains poor. Fortunately, there have been renewed and continued interests and active research in developing other molecularly targeted agents in HCC during the past few years. While there is early evidence of antitumor activity of several agents in phase I/II studies, phase III efforts with a few targeted agents have failed, highlighting the challenges of new drug development in HCC. This review summarizes the current status of other molecularly targeted agents under development in advanced HCC.

Keywords: EGFR inhibitors; Met inhibitors; bevacizumab; brivanib; everolimus; hepatocellular carcinoma; linifanib; sorafenib; sunitinib; targeted agents.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The author has advisory roles with Sanofi-aventis, Eisai, Bristol-Myers Squibb, Abbott Laboratories and Eisai and has received research support from Bayer, Onyx, Lilly-ImClone and Novartis.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Alberts S., Fitch T., Kim G., Morlan B., Dakhil S., Gross H., et al. (2011) Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial. Am J Clin Oncol, in press. - PMC - PubMed
    1. Arora A., Scholar E. (2005) Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 315: 971–979 - PubMed
    1. Bekaii-Saab T., Markowitz J., Prescott N., Sadee W., Heerema N., Wei L., et al. (2009) A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res 15: 5895–5901 - PMC - PubMed
    1. Carlin C., Simon D., Mattison J., Knowles B. (1988) Expression and biosynthetic variation of the epidermal growth factor receptor in human hepatocellular carcinoma-derived cell lines. Mol Cell Biol 8: 25–34 - PMC - PubMed
    1. Chan S., Chung H., Wang L., Lim R., Picus J., Boyer M., et al. (2012) Efficacy of belinostat in advanced hepatocellular carcinoma (HCC): Phase I and II multicentered study of the Mayo Phase 2 Consortium (P2C) and the Cancer Therapeutics Research Group (CTRG). J Clin Oncol 30(Suppl. 4): abstract 259.